Abstract
Breast cancer is one of the major causes of female morbidity and mortality, accounting for ~25% of the total cancer cases in women. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic α subunit (
PIK3CA
) mutations serve a major role in downstream signaling of receptor tyrosine kinases. The present study aimed to elucidate the frequency of exon 9 and 20 mutations of
PIK3CA
and their role in disease progression. A total of 118 tumor samples from confirmed breast cancer patients were collected from the histopathology laboratory at King Fahd Hospital of the University (Al-Khobar, Saudi Arabia). Sanger sequencing was performed on extracted DNA to identify the mutations on exons 9 and 20 of
PIK3CA
. The results were further validated by competitive allele-specific TaqMan polymerase chain reaction. Three mutations, namely E542K and E545K within exon 9, and H1047R within exon 20, were observed in 25 patients (21.2%). Among these, 18 patients carried the H1047R mutation of the kinase domain, while the remaining 7 patients carried mutations in the helical domain.
PIK3CA
mutations were associated with the estrogen receptor-positive/progesterone receptor-positive (ER
+
/PR
+
) group of tumors in contrast to the ER
−
/PR
−
group (P=0.021). Furthermore, it was observed that the
PIK3CA
mutation was associated with a poor disease prognosis. Taken together, the current study emphasized the potential of
PIK3CA
mutations as an important biomarker for breast cancer classification and the possible use of
PIK3CA
inhibitor as targeted therapy for breast cancer.